How often should I get scans to monitor my HER2-Positive Breast Cancer

Scan Frequency for HER2-Positive Breast Cancer Monitoring

This is an important question, and the answer depends on several factors specific to your situation. Let me explain what the medical evidence shows and what questions to ask your oncologist.

What the Evidence Shows

The frequency of scans varies significantly based on where you are in your treatment journey:

During Active Treatment

When you're actively receiving chemotherapy, targeted therapy (like trastuzumab/Herceptin), or other anti-HER2 treatments, scans are typically done more frequently—often every 8-12 weeks—to assess how well the treatment is working.

After Treatment Completion

This is where it gets more individualized. According to the CancerPatientLab webinars featuring Dr. [removed] Lopez-Correa (an MD PhD who navigated her own HER2-positive breast cancer), the standard approach has traditionally been:

• Every 6 months for the first 2-3 years after completing treatment
• Annually after 5-6 years out from treatment

However, Dr. [removed]-Correa notes that this is evolving, and some patients may continue more frequent monitoring depending on their risk factors.

Important Factors That Affect YOUR Scan Schedule

Your oncologist will consider:

1. Stage at diagnosis - Earlier stage cancers may need less frequent monitoring
2. Response to treatment - How well your cancer responded to therapy
3. Biomarkers and genetic factors - Your specific tumor characteristics (like the HER2 amplification level, hormone receptor status, Ki-67 score)
4. Circulating tumor DNA (ctDNA) testing - Some patients use blood tests like Signatera to monitor for minimal residual disease, which may influence imaging frequency
5. Your individual risk profile - Age, other health conditions, family history

The Emerging Role of Liquid Biopsies

An important development mentioned in the webinars is that some oncologists are now using circulating tumor DNA (ctDNA) tests to help guide imaging decisions. Rather than scanning on a fixed schedule, doctors may:

• Use ctDNA results to increase imaging frequency if the test shows concerning signals
• Use ctDNA to confirm findings before making treatment changes
• Monitor tumor burden over time to understand your individual "doubling time"

As Dr. [removed]-Correa explains, this allows for more personalized monitoring rather than one-size-fits-all schedules.

Questions to Ask Your Oncologist

To develop the right scan schedule for YOUR situation, ask:

1. "Based on my stage, treatment response, and biomarkers, what scan frequency do you recommend for me?"

2. "Are there any biomarkers in my tumor (like high HER2 expression levels or other factors) that would suggest more or less frequent monitoring?"

3. "Would circulating tumor DNA testing (like Signatera) be helpful in my case to guide when we do imaging?"

4. "How long will I need regular scans, and when might we transition to less frequent monitoring?"

5. "What imaging modality do you recommend—CT, MRI, PET scan—and why?" (This matters because, as noted in the webinars, some patients switch from CT to MRI after several years to reduce cumulative radiation exposure)

6. "If I have a positive ctDNA result, does that automatically mean we treat, or would we confirm with imaging first?"

Important Context

The webinars emphasize that scan frequency should be individualized, not based on a rigid protocol. Your doctor will balance:

• The benefit of catching recurrence early
• The risks of cumulative radiation exposure
• The anxiety that frequent monitoring can create
• Your personal preferences and values

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.